Would you hold a PARP inhibitor in the perioperative period for an ileostomy reversal in a patient who has completed primary debulking surgery followed by chemotherapy?

Community
Company
News
Contact Us
Sign in

Topics: Gynecologic Cancers • Ovarian Cancer

If so, for how long? What is your general practice for managing PARP inhibitors in the peri-operative period?

Related Questions

Would you use a PARP inhibitor as treatment for recurrent platinum-sensitive ovarian cancer with a RAD51 (or other moderate-penetration HRD germline) mutation?

Would you recommend SBRT in the adjuvant settings for a solitary metastasis focus in the abdominal wall resected to R1 in a young and healthy patient with clear cell ovarian cancer?

How would you approach adjuvant therapy for a patient who was diagnosed with surgically staged and completely resected stage II high-grade serous ovarian cancer while she prepared for neoadjuvant chemoradiation for rectal cancer?

In the absence of a cohesive workflow guiding the use of PARPi in ovarian cancer since the 2022 FDA approval withdrawals, what is your general approach to PARPi usage in the front-line and recurrent setting?

What platform do you use for HRD testing of ovarian cancers and why?

What are your top takeaways in Gynecologic Cancers from ASCO 2023?

Do you personally review all imaging you order or rely judiciously on radiologist interpretation?

What adjuvant therapy would you recommend for a patient with high grade serous ovarian cancer who has surgically confirmed unresectable disease after a partial response to 6 cycles of a platinum doublet?

How have you incorporated mirvetuximab into the treatment of platinum-resistant ovarian cancer?

Do you recommend bevacizumab with front-line platinum-based adjuvant chemotherapy for fully resected stage III ovarian clear cell carcinoma?